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Abstract
Background: Pretreatment auxological variables, such as birth size and parental heights, are
important predictors of the growth response to GH treatment. For children with missing
pretreatment data, published prediction models cannot be used.
The objective was to construct and validate a prediction model for children with missing
background data based on the observed first-year growth response to GH. The accuracy and
reliability of the model should be comparable with our previously published prediction model
relying on pretreatment data. The design used was mathematical curve fitting on observed growth
response data from children treated with a GH dose of 33 μg/kg/d.
Methods: Growth response data from 162 prepubertal children born at term were used to
construct the model; the group comprised of 19% girls, 80% GH-deficient and 23% born SGA. For
validation, data from 205 other children fulfilling the same inclusion and treatment criteria as the
model group were used. The model was also tested on data from children born prematurely,
children from other continents and children receiving a GH dose of 67 μg/kg/d.
Results: The GH response curve was similar for all children, but with an individual amplitude. The
curve SD score depends on an individual factor combining the effect of dose and growth, the
'Response Score', and time on treatment, making prediction possible when the first-year growth
response is known. The prediction interval (± 2 SDres) was ± 0.34 SDS for the second treatment
year growth response, corresponding to ± 1.2 cm for a 3-year-old child and ± 1.8 cm for a 7-year-
old child. For the 1–4-year prediction, the SDres was 0.13 SDS/year and for the 1–7-year prediction
it was 0.57 SDS (i.e. < 0.1 SDS/year).
Conclusion:  The model based on the observed first-year growth response on GH is valid
worldwide for the prediction of up to 7 years of prepubertal growth in children with GHD/ISS,
born AGA/SGA and born preterm/term, and can be used as an aid in medical decision making.
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Background
In a clinical setting, when considering prescribing growth
hormone (GH) treatment for a short or slowly growing
child, tools that reliably predict the growth response to
treatment are welcome. Published prediction models rely
on pretreatment auxological variables and often on paren-
tal heights [1-5], variables that are often impossible to
obtain. In reality, missing data on, for example, birth size
and gestational age, may also complicate the decision of
what disease-specific model to use.
Most prediction models give information on the esti-
mated growth response for only the first or the first 2 years
of treatment [1-5]. Growth response on treatment is posi-
tively influenced by a young age at the start of treatment
[1-6] and, as height at onset of puberty highly influences
final height [7], a model for prediction of not only annual
but long-term prepubertal growth response on GH treat-
ment would be a valuable contribution to the treatment
decision-making process.
The aim of this project was to develop a prediction model
for growth in response to GH in prepubertal children,
relying only on data that could be obtained in different
health settings, and also in adopted and immigrant chil-
dren (i.e. where information on birth size, gestational age,
growth during early life and parental heights are missing).
However, accuracy and reliability should not be reduced
compared with our previously published prediction
model relying on pretreatment data [2,5].
It is an empirical finding that first year growth in response
to GH is an indicator of the growth response in subse-
quent years of treatment, a finding confirmed in models
predicting growth response on a yearly basis in children
with GH deficiency (GHD) [1,2,5] or non-GH-deficient
short children born small for gestational age (SGA) [3,5]
or appropriate for gestational age (AGA; children with
ISS) [2,5,6]. However, an accurate model for predicting
long-term growth in response to GH in children with
missing birth data has not yet been presented.
The hypothesis in the present study was that the observed
first-year growth response to a certain dose of GH in prepu-
bertal children would provide enough information with
which to construct a prediction model with a model error
low enough to be useful in clinical practice for the prediction
of future prepubertal growth response on GH treatment. By
this, it should be possible to individualize the GH dose and
thereby the growth outcome until the onset of puberty.
Patients and Methods
Patients
Growth response data until puberty were used from pre-
pubertal children on GH treatment in Sweden retrieved
from the National Registry or from clinical trials. Every 3
months, the dose of GH was adjusted according to weight,
height was measured with a standardized technique, and
pubertal status and compliance were checked.
Model group
Growth data during GH treatment were obtained from 162
prepubertal children born at term (19% girls; 80% GH-defi-
cient; 23% born SGA) and for whom 2 years or more of pre-
pubertal growth data were available and age was 2.5 years or
more at the start of treatment (Table 1). The model group in
this paper is a subset of the group of patients modeled in a
previous study [2], having at least one measurement after 1
year of treatment and a second after 2–7 years of treatment.
An arginin-insulin tolerance test (AITT) was used to confirm
diagnosis with GHD or ISS (cut off, the 'old 10 μg/L') [8]. GH
dose was approximately 33 μg/kg/d (Table 1). No child with
combined pituitary insufficiency or chronic disease poten-
tially affecting growth was included. Children with a recog-
nized syndrome were also excluded, apart from a few
children with Silver-Russell syndrome who had a birth
length or weight below -2 SDS [9].
Validation group
Data from 205 children (28% girls; 74% GH-deficient;
43% born SGA), fulfilling the same inclusion and treat-
ment criteria as the model group, were used to validate the
model (Table 1).
Test groups
Children born prematurely
The model was applied to data from a separate group of
19 children born prematurely with a gestational age of
30–36 weeks (68% SGA) and given GH at a dose of 33 μg/
kg/d (Table 2).
Children from non-European continents
Growth data for 78 children from non-European continents
(four from Africa, 24 from Asia, 24 from other continents
and 26 who had parents from different continents) given GH
at a dose of 33 μg/kg/d were also tested in the model. Out of
these 78 children, 28 had a diagnosis of GHD and 24 a diag-
nosis of ISS; in 26 children a GH-provocation test had not
been performed. Birth data were missing in the majority of
these patients (Table 2).
Children treated with a higher GH dose
In order to study the robustness of the model, growth data
from 15 children treated with a GH dose of 67 μg/kg/d,
but otherwise fulfilling all inclusion criteria for the model,
were assessed.
Methods
Auxology
Birth weight SDS and birth length SDS used in the algo-
rithms were calculated according to Niklasson et al.
[10,11]. For the prepubertal growth SDS calculation weBMC Medical Informatics and Decision Making 2009, 9:1 http://www.biomedcentral.com/1472-6947/9/1
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used the formula of the childhood component [12] of the
current Swedish growth references [13].
Curve fitting for a non-linear growth-response curve
During our earlier work for the prediction of the 0–1 year
and 0–2-year growth responses to GH treatment in prepu-
bertal children with GHD and ISS, models were con-
structed based exclusively on data that could be obtained
from before the start of GH treatment, heavily relying on
auxological data at birth and during the first 2 years of life
and parental heights [2].
Measurements of growth response were obtained at differ-
ent treatment times; for adequate correction of these dif-
ferences a non-linear growth-response curve was
computed by curve-fitting. It was based on observed lon-
gitudinal measurements from a subset of the model group
of patients reported previously [2] during 1–7 prepuber-
tal-years of GH treatment. This subset of the model group
was used in the previous study [2] to establish the formula
Δheight SDSPred(t) = Fa(t)+M*Fb(t), where the individual
parameters, M, and the form of the curves, Fa(t) and Fb(t),
are fitted with alternating least squares. For fixed curves Fa
and Fb, each individual parameter, M, was fitted with the
regression y = xb+a, with regression weight b = M, inter-
cept a = 0, response y = delta ht SDS(t) - Fa(t) and predic-
tor x = Fb(t) for all observed treatment times t ≥ 0. In this
paper, the same model group was used to estimate each
individual regression weight, b = M, for the (fixed)
response curve using only two measurement points, t = 0
and t = 1, resulting in a curved regression line that can be
extrapolated after 1 year of treatment. In this way, the
extrapolated response curve can be applied as a prediction
model at 1 year of treatment, aiming to avoid the need for
pretreatment auxology data.
Furthermore, the old complex equations, Fa(t) and Fb(t),
were reparameterized to facilitate more simple clinical
interpretation, especially for equation Fb(t) (Figure 1).
Our previous equation, Fa(t) [2], was replaced by the
equationBasic Growth: FBG(t) = elog (1 + t*(0.205 - 1/(1 +
2.1*t))) and the equation Fb(t) [2] was replaced by the
equationCatch Up: FCU(t) = t/(t + 0.894), which is an asymp-
totic catch-up function, whereas Fb(t) is not.
The accuracy of this reparameterization was assessed by
evaluating the maximum absolute deviation between the
old [2] and new growth response curves. For all theorical
values of M between 0 and 5, which is the biological
Table 1: The characteristics of the children included in the model group (n = 162) and in the validation group (n = 205).
Model group
(30 girls, 132 boys)
Validation group
(58 girls, 147 boys)
Variables Median Min Max n Median Min Max n
At birth
Gestational age (weeks) 40 37 42 162 40 37 42 205
Height at birth SDS -1.07 -2.65 2.6 162 -1.48 -5.75 1.9 205
Weight at birth SDS -0.88 -2.75 3.24 162 -1.28 -4.5 1.81 205
At GH start
Age at start of GH treatment (yrs) 8.3 2.78 13.92 162 7.78 2.51 12.53 205
Height SDS -2.91 -4.59 -1.54 162 -2.84 -4.76 -1.29 205
Weight SDS -2.58 -4.29 0.73 162 -2.5 -5.28 1.28 205
Weight for height SDS -0.54 -3.31 3.85 162 -0.61 -3.08 4.09 205
Body mass index (kg/m2) 15.4 12.88 23.98 162 15.19 12.25 23.76 205
Change in height SDS during pre-treatment year 0.02 -0.85 0.58 144 0.01 -0.71 0.68 186
Target height SDS -0.75 -2.4 1.26 162 -0.66 -2.71 0.94 205
Fathers height SDS -1.13 -4.93 1.91 162 -0.83 -3.86 2.02 205
Mothers height SDS -1,25 -3.55 1.22 162 -1.25 -3.55 1.55 205
Diff MPH SDS -2.26 -4.98 -0.8 162 -2.27 -5.11 -0.41 205
GHmax during AITT (mU/L) 19.8 1.7 229.4 160 21 2.4 124.88 181
GHmax of 24 h profile (mU/L) 34.65 3.88 81.08 64 32.8 7.55 235.37 94
IGF-I at GH start 96.25 11.68 219 68 80 8 330 150
IGF-I SDS -0.6 -6.69 1.38 68 -1.1 -7.43 3.03 150
GH dose (ug/kg.day) 0.033 0.027 0.04 162 0.033 0.023 0.043 205
During treatment
Change in height SDS first yr 0.72 0.3 2.26 162 0.74 0.07 2.56 205
Change in height SDS during 2 yrs 1.15 0.4 2.88 162 1.14 0.23 3.12 205
Growth hormone (mU/L) levels were analysed at GP-GRC, GU, with Delfia monoclonal assay, Wallac, Finland, standard WHO IRP 80/505, [8].
Insulin-like growth factor I (IGF-I) (μg/L) were analysed according to Blum and Breier [26] and transformed into SD scores (SDS) according to 
gender and age of our prepubertal reference [27].BMC Medical Informatics and Decision Making 2009, 9:1 http://www.biomedcentral.com/1472-6947/9/1
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observed range, the maximum absolute deviation was
0.01 SDS over the first 4 years of treatment and 0.1 SDS
over the remaining 5–7 years of treatment. The maximum
deviation is much smaller than the measurement error.
The individual growth-response curves can be computed
by adding the two equations, where only FCU(t) is multi-
plied by an individual factor, a model parameter MModel
[2]. This individual model parameter is dependant on the
GH dose (here 33 μg/kg/d) and the individual growth
response. The parameter MModel was predicted for the indi-
vidual child in our previous work [2] from pretreatment
variables according to background and investigational
data. The resulting predicted individual growth response
was given in the algorithm by equation: Δheight
SDSPred(t) = FBG(t) + MModel *FCU(t).
The clinical concept 'Response Score' (RS)
The MModel(Individual) *FCU(t) part of the equation provides
an individual predicted catch-up growth curve over the
prepubertal years, approaching an asymptotic value (Fig-
ure 1). This gives a value for the mathematical catch-up
level for each individual child, expressed by the GH
growth-response equation: RSpred = MModel *FCU(t = 8)
where time 't' is approaching infinity and FCU(t = 8) = 1.
The total growth response during time 't' can be expressed
by the growth response equation: Δheight SDS (t) = FBG(t)
+ RSpred * FCU(t) (Figure 2 left panel). A general "basic
growth" function (FBG(t)) is added to a general "Catch-
Up" function (FCU(t)) with an individual catch-up level
(RSpred), which can be monitored or predicted. The
response score gives a measure of growth in response to
GH, independent of treatment duration.
Using the observed Response Score (RS) for prediction
For each observed measurement of individual growth
response on GH treatment (Δheight SDSobs), it is possible
to estimate the individual RS by defining the following
Response Score equation: RS(t) = (Δheight SDSobs  -
FBG(t))/FCU(t) (Figure 2 middle panel). Thus, the RS can
be estimated with only four variables: height at the start of
treatment and after at least 1 year of GH treatment [14],
gender and age. These variables are used to compute the
Δheight SDSobs 
1 yr and produces an individual RS1 yr.
Using the RS1 yr, the Δheight SDS(t) on GH treatment over
time (t) can be predicted with the model provided that the
child remains prepubertal.
This gives the prediction model: Δheight SDS(t) = FBG(t) +
RS1 yr * FCU(t)
Table 2: The characteristics of the children included in the test groups of children born prematurely (n = 19) and in children from 
other continents (n = 78).
Preterm
(6 girls, 13 boys)
From foreign continents
(27 girls, 51 boys)
Variables Median Min Max n Median Min Max n
At birth
Gestational age (weeks) 35 32 36 19 38.5 27 41 28
Height at birth SDS -2.55 -8.09 1.43 19 -1.76 -3.91 0.38 6
Weight at birth SDS -2.25 -6.12 0.11 19 -1.27 -3.95 0.63 8
At GH start
Age at start of GH treatment (yrs) 6.38 3.02 10.1 19 8.35 3.13 13.47 78
Height SDS -2.81 -4.08 -2.01 19 -3.27 -6.31 -0.74 78
Weight SDS -2.78 -5.15 -1.56 19 -3.11 -5.66 1.12 78
Weight for height SDS -0.97 -3.29 0.71 19 -0.71 -3.8 4.23 78
BMI (kg/m2) 14.5 12.18 16.5 19 15.35 11.49 22.23 78
Change in height SDS during pre-treatment year 0 -0.45 0.52 17 0.07 -0.73 0.59 69
Target height SDS -0.58 -1.89 1.26 19 -1.23 -3.72 0.5 39
Father height SDS -1.13 -3.41 1.3 19 -2.04 -4.62 0.54 39
Mother height SDS -0.84 -3.39 1.55 19 -2.07 -5.85 0.4 41
Diff MPH SDS -2.23 -3.43 -1.27 19 -1.76 -4.35 1.27 39
GHmax during AITT (mU/L) 24.15 11 70.4 18 20.72 1.09 135.57 30
GHmax of 24 h profile (mU/L) 19.95 14.3 48.05 11 42.69 12.37 88.79 43
IGF-I at GH-start 60 19 187 18 78 12 259 19
IGF-I SDS -1.57 -5.42 0.72 18 -1.35 -7.02 1.75 19
GH dose (ug/kg.day) 0.037 0.027 0.043 19 0.033 0.023 0.047 78
During treatment
Change in height SDS first yr 0.67 0.47 1.16 19 0.68 -0.1 1.74 78
Change in height SDS during 2 yrs 0.92 0.63 1.69 19 1.06 0.11 2.79 78BMC Medical Informatics and Decision Making 2009, 9:1 http://www.biomedcentral.com/1472-6947/9/1
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where FBG(t) = elog (1 + t*(0.205 - 1/(1 + 2.1*t))) and
FCU(t) = t/(t + 0.894); t = GH treatment time in years.
For each child, the RS(t) value that is calculated from an
observed change in height SDS (Δheight SDSt
obs) should
remain constant during GH treatment, as long as no con-
comitant distress interferes with growth.
Ethics
The study was approved by the Ethics Committee of the
Medical Faculties of the Universities of Göteborg, Lund,
Linköping, Uppsala and Umeå and of the Karolinska
Institute. Informed consent was obtained from the par-
ent(s) or person(s) with custody of the child and from the
child, where appropriate.
Results
Observed response score for prediction
Figure 2 right panel shows the observed growth response,
for comparison with the predicted growth response made
after 1 year on treatment, on the four variables: age, gen-
der, height at start of treatment and height after 1 year on
GH treatment.
Validation of long-term growth in response to GH on data 
from children born AGA/SGA at term
The observed individual growth responses to GH in 205
children during 1–7 years of prepubertal growth were
used to validate the predictions made based on the
observed first-year growth and the corresponding
Response Score. The validation group was examined both
in total and subdivided into children born AGA and SGA;
data are presented in Table 3 together with corresponding
data from the group used to construct the model. The
SDres of the validation group is as low as for the model
group, indicating that the model gives an accurate estima-
tion of the individual growth response curve for the 1–7
years of prepubertal growth on GH treatment. The SDres
was 0.17 SDS for 1–2 years of treatment and 0.57 SDS for
the total period of 1–7 years of treatment (i.e. < 0.1 SDS/
year during 6 years of GH treatment). A separate analysis
showed no significant difference between the growth
response to GH treatment in children born AGA and chil-
dren born SGA (Table 3).
Group validation of estimated Response Scores
The values for the Response Scores over treatment time t
(RS(t)) were calculated for 51 of the 162 children on GH
treatment in the model group for whom prepubertal
growth measurements were available at precise annual
intervals during the first 4 years of treatment (Figure 3).
When the RS equation was applied (i.e. validated) on data
from 54 children from the validation group fulfilling the
same criteria, the mean RS values remained constant as for
the model group (i.e. the results were consistent).
The similarity with respect to mean growth in response to
GH over all years shows that the model and validation
groups are clinically comparable with respect to the aver-
age growth response; the difference between group mean
yearly changes in height SDS is a maximum of 0.02 SDS.
The model and validation groups were also studied after
subdivision into quartiles according to the RS1 yr level; the
mean and range at each yearly measurement remained the
same for each quartile (data not shown).
Test on data from children born prematurely
The prediction model based on RS1 yr was tested on a sep-
arate group of 19 children born prematurely at a gesta-
tional age of 30–36 weeks, Table 4. The diminishing
number of children during the treatment period reflects
the numbers remaining prepubertal. The SDres are consist-
ent with the results for the children born at term. Dividing
the prematurely born children into AGA and SGA groups
gave very small numbers, but there was no difference in
the SDres for the two groups.
Graphic illustration of the two equations that, when com- bined, produce the non-linear growth response curve Figure 1
Graphic illustration of the two equations that, when 
combined, produce the non-linear growth response 
curve. The hyperbolic equation FCU(t) can be regarded as a 
'catch-up' equation, (by multiplying with the individual param-
eter MModel) asymptotically modulating individual amplitude 
with time. The "1" on the y-axis gives the asymptotic value of 
the FCU(t), and the Equation FBG(t) can be interpreted as a 
'baseline growth' equation that introduces a delayed general 
growth response with a greater relative impact on individuals 
with low levels of catch-up growth than on individuals with 
high levels of catch-up growth.
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Test on data from children coming from other continents
The prediction model was tested, and found to be valid on
growth data from 78 children from other continents who
seldom had complete data on birth size, pre-treatment
growth and/or parental heights (Table 4).
Test on data from children treated with an increased GH 
dose
In order to study the robustness of the model for differ-
ences in GH dosing, data from children fulfilling the
inclusion criteria but being treated with a higher GH dose
(67 μg/kg/d) were checked in the prediction model. The
results are presented in Table 4; the SDres was of the same
low magnitude as for children treated with the lower GH
dose, showing that the model may also be applicable in
such patients.
Discussion
The hypothesis for the present study was confirmed, i.e.
the observed first-year growth response on GH treatment
contained enough information to be used for prediction
of up to 7 years of prepubertal growth on GH treatment
with a model error below 0.1 SDS/year for the entire 7-
year period. The validated model is accurate and reliable
and only needs information on four variables: gender,
age, height at start of GH treatment, and observed first-
year growth response to GH. This information is easily
obtained in a clinical setting. The model can also be used
for the children of immigrants for whom early growth
data and parental height data are missing, as no pre-treat-
ment investigations are necessary. Information on first-
year growth in response to GH treatment makes it possi-
ble to estimate an individual Response Score, which can
be used in the model in place of the pre-treatment data
used in our previous prediction models to give equally
accurate growth predictions [2-5].
A prerequisite for construction of the model is that we can
demonstrate that the growth response to GH treatment
can be fully described by a common equation for prepu-
bertal non-syndromic children, clinically classified as GH-
deficient/ISS, AGA/SGA and born later than 30 weeks of
GH response chart for visualization of Response Scores (RS) on different levels (i.e. growth responses for children with varia- ble individual responsiveness to GH) Figure 2
GH response chart for visualization of Response Scores (RS) on different levels (i.e. growth responses for chil-
dren with variable individual responsiveness to GH). Left panel: The RS chart is given with 'isolines' ('channels') for RS = 
1, 2, 3 and 4 which is indicated in the figure. For the individual child at treatment time 1 year (x-axis), the observed growth 
response (Δheight SDS) is found on the y-axis to the left and following the corresponding curve the individual RS can be found 
to the right. Middle panel: Observed first-year Δheight SDS on treatment for three prepubertal children from the validation 
group (filled circles). The individual calculated Response Score (dotted line) is found on the right axis. The function for the 
Response score is: RS(t) = (Δheight SDSobs - FBG(t))/FCU(t), where FBG(t) = elog (1 + t*(0.205 - 1/(1 + 2.1*t))) and FCU(t) = t/(t 
+ 0.894); t = GH treatment time in years. Right panel: Individual Response Scores from the same three children, based on 
observed Δheight SDS on treatment at different time points (filled circles at treatment time 2, 3, 4, 5 and 6 years) in compari-
son with the predicted (dotted line). Response Score was consistent over time within an individual child, and the inclusion in 
the model of measurements made later than 1 year after the start of GH treatment are acceptable.
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gestation. Using growth-response equations which are
modulated by an individual parameter depending on
individual responsiveness and GH dose, we show that the
model works on empirical data from an independent
group of 205 children fulfilling the inclusion criteria for
the model group and also on data from more than 100
children with short stature as a result of other diagnoses.
Thus, the present model was demonstrated to be valid on
independent data from children classified as GH-defi-
cient/ISS, born AGA/SGA, born at term/preterm (> 30
weeks gestational age), of Swedish or non-Swedish origin
and receiving a GH dose close to 33 ug/kg/d or 67 ug/kg/
d. Although these results are valid for the model, the
groups of children treated with higher dose or born pre-
term are limited in number and data from more children
are needed for further validation.
The performance of the present model, demonstrated by
the SDres for the second year, is 0.17 SDS, corresponds to
a 95% prediction interval of ± 0.34 SDS with very similar
results for the model group and the validation group. This
gives a second year prediction interval of ± 1.2 cm for a 3-
year-old child and ± 1.8 cm for a child aged 7 years. For 1–
4 years of treatment, the SDres is as low as 0.38 SDS (i.e.
0.13 SDS/year) and for the period from 1–7 years, the
SDres is 0.57 SDS (i.e. < 0.1 SDS/year). Thus, knowing only
the first-year growth response to GH treatment makes it
possible to predict the total growth response for up to 7
prepubertal years (i.e. until the start of puberty). This is of
great clinical significance as height at the onset of puberty
has an important influence on adult height [7,8,15-18]. In
clinical practice, information on growth response can be
used to adjust the GH dose and by that improve prepuber-
tal height outcome.
In this project a new concept was introduced: the individ-
ual Response Score at 1 year which is dependent on both
the GH dose and the GH responsiveness of the child. For
each child, it is now possible to calculate an individual
Response Score value using the observed change in height
SDS during a given treatment time period. Due to sea-
sonal variation in both spontaneous growth and growth
during GH treatment [14,19], the recommendation must
be to allow a full year of growth for use in the prediction
model. A height measurement obtained at more than 12
months of treatment will still be useful for calculation of
the Response Scores, due to the growth response curve
being non-linear. As the observed height will be very
important for the accuracy of the prediction, measure-
ment error should be minimized by using a standardized
Table 3: Model error for the prediction of the 1–7-year GH growth response expressed in Dheight SD scores for the model group and 
the validation group separately: for the total group and subdivided into children born AGA or SGA.
Model group Validation group
Total group: n SDres SDstudRes Total group: n SDres SDstudRes
1–2 year 162 0.17 1.00 1–2 year 205 0.19 1.11
1–3 years 97 0.29 1.00 1–3 years 111 0.28 0.97
1–4 years 53 0.38 1.00 1–4 years 58 0.35 0.90
1–5 years 34 0.43 1.00 1–5 years 40 0.45 1.04
1–6 years 17 0.48 1.00 1–6 years 29 0.40 0.84
1–7 years 7 0.57 1.00 1–7 years 9 0.43 0.75
AGA: AGA:
1–2 year 125 0.17 0.99 1–2 year 117 0.19 1.12
1–3 years 69 0.28 0.96 1–3 years 63 0.26 0.90
1–4 years 39 0.39 1.02 1–4 years 31 0.31 0.82
1–5 years 21 0.44 1.03 1–5 years 18 0.39 0.92
1–6 years 8 0.45 0.95 1–6 years 15 0.42 0.88
1–7 years 7 0.57 1.00 1–7 years 3 0.26 0.45
SGA: SGA:
1–2 year 37 0.18 1.05 1–2 year 88 0.19 1.09
1–3 years 28 0.31 1.08 1–3 years 48 0.30 1.05
1–4 years 14 0.36 0.93 1–4 years 27 0.37 0.98
1–5 years 13 0.41 0.96 1–5 years 22 0.49 1.13
1–6 years 9 0.50 1.04 1–6 years 14 0.37 0.79
1–7 years 0 - - 1–7 years 6 0.49 0.87
SDres = root mean square error of the residuals.
SD stud Res = SDres/SDresModelgroup
For a reliable model, the SDres should be similar, or lower, for the validation group compared with the SDres from the model group.BMC Medical Informatics and Decision Making 2009, 9:1 http://www.biomedcentral.com/1472-6947/9/1
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measuring technique, with measurements preferably per-
formed by the same person and at the same time of the
day. Using the obtained growth responset and thereby the
estimated RSt, the growth response during a selected
future period can be predicted.
In many children, information on heredity (parental
heights), gestational age, birth size and/or pre-treatment
growth are missing and are impossible to retrieve. For
such children, a test-treatment year is often used to evalu-
ate GH responsiveness. Therefore, a model that is accurate
for use in patients with many different diagnoses of short
stature is crucial as otherwise insufficient information pre-
cludes the use of any prediction model. The prediction
model presented can be used in such children with the
same degree of accuracy as the model that includes pre-
treatment data [2,5]. The model can also be used in a
healthcare system preferring a year of test-treatment
instead of pre-treatment investigations. However, for chil-
dren in whom pre-treatment data are known, a model that
uses pre-treatment data is preferable in order to optimize
treatment during the first year and our suggestion is to use
our previously published model to predict height gain
during the first year [2,5] and when deciding whether or
not to initiate treatment. The previously published model
should also be used for selecting the GH dose for the first
The group mean values ± SEM for the Response Score calcu- lated at 1, 2, 3 and 4 years of GH treatment Figure 3
The group mean values ± SEM for the Response 
Score calculated at 1, 2, 3 and 4 years of GH treat-
ment. The equation was applied to data from children who 
have values from all four annual measurements on GH treat-
ment: the model group (n = 51) and validation group (n = 
54). The observed height at the yearly measurement is used 
for estimation of the RS (1–4 years). This shows that a relia-
ble model gives constant RS values during 4 years of GH 
treatment.
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Table 4: Test of growth in response to GH treatment in different 
cohorts of children: born preterm from other countries or 
treated with 67 μg/kg/d of GH in children born preterm or at 
term.
Children born preterm (30–36 w)
GH dose 33 μg/kg/d
n SDres SDstudRes
1–2 year 19 0.16 0.93
1–3 years 15 0.31 1.07
1–4 years 7 0.44 1.15
1–5 years 5 0.27 0.63
1–6 years 4 0.51 1.07
1–7 years 2 0.47 0.83
Children from other continents
GH dose 33 μg/kg/d
n SDres SDstudRes
1–2 year 78 0.18 1.07
1–3 years 42 0.25 0.88
1–4 years 20 0.35 0.9
1–5 years 10 0.34 0.79
GH dose of 67 μg/kg/d
Born at term
n SDres SDstudRes
1–2 year 15 0.19 1.13
1–3 years 7 0.31 1.09
1–4 years 2 0.37 0.95
GH dose of 67 μg/kg/d
Born preterm
n SDres SDstudRes
1–2 year 7 0.17 1.01
1–3 years 2 0.26 0.90
SDres = root mean square error of the residuals.
SD stud Res = SDres/SDresModelgroupBMC Medical Informatics and Decision Making 2009, 9:1 http://www.biomedcentral.com/1472-6947/9/1
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treatment years, as the younger the child is at the start of
treatment, the better the response.
The variation in mean GH responsiveness between groups
of children with different diagnosis is well known [20].
This has been the rationale behind published prediction
models for use in different cohorts of children [1-5]. How-
ever, it is likewise well known that within every diagnostic
group, there is great variation in growth response between
individuals [21,22], as well as overlap between diagnostic
groups. This continuum in GH responsiveness is the
rationale for the inclusion of groups of children based on
diagnosis in our work with the prediction of growth in
response to GH, despite the fact that such cohorts are
often defined based on arbitrary cutt-off values/statistics.
Other evidence for the continuum in GH responsiveness
is the overlap in growth responses using different GH
doses within patients with the same diagnosis [3] and the
wide range in GH dose needed to obtain a predefined
serum insulin-like growth factor I (IGF-I) level [22]. The
variation in GH dose needed to affect growth has previ-
ously been discussed in terms of misdiagnosis [23], but in
recent years is more often seen as the expression of varia-
tions in individual responsiveness to GH [20,24,25]. In
the present model, an individual factor, a Response Score,
is expressed that also includes the effect of a fixed GH
dose. In future, this factor should be investigated further
and a dosing module added to the model.
Conclusion
In conclusion, data are presented showing that the growth
response to GH treatment can be described by a common
algorithm for prepubertal non-syndromic children from
different ethnic and geographic backgrounds, clinically
classified as GHD/ISS, AGA/SGA and born later than 30
weeks of gestation. For each child, there is an individual
parameter modulating the amplitude and timing of the
response that depends on the child's GH responsiveness
(constant) and treatment dose (here named Response
Score). The observed first-year growth response to GH
treatment reveals this value.
We provide a prediction model that is valid for the major-
ity of short children worldwide in whom growth-support-
ive therapies are considered, despite the lack of historical
auxological data on the child and without the need for
any extensive investigations. The advantage of the present
model is the 7-year reliability (i.e. the entire prepubertal
period). The drawbacks are that an observed first-year GH
growth response is needed and that the model is currently
only validated for a GH dose close to 33 μg/kg/d. In order
to increase the applicability of the mode, a collaborative
study will be needed. This will be of importance in order
to add a dose module for improved individualizing of the
GH dose. Using this decision-making tool, it is possible to
make reliable evidence-based decisions on whether, or
how, to continue GH treatment in the individual child.
The model presented here can be used in non-syndromic
short children, independently of birth size, and provides
the best prediction accuracy available [1,3,4] (i.e. as high
as previously obtained models using pretreatment infor-
mation). The model can also serve as a tool for identifying
those children who may benefit from long-term GH treat-
ment, and will help to determine the GH dose needed
during the first years of treatment in order to optimize
individual catch-up growth.
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